US Edition
Number of megarounds drop 38% in first half as biotechs struggle against worsening slump
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Number of megarounds drop 38% in first half as biotechs struggle against worsening slump
Even biotech's "haves" are struggling. The sector's fraught funding environment has been in a slump going on three years, and it's created a world of "haves and have-nots" for private drug development startups. Companies with ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium